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To the Editor: 
lot formation within a deep vein is called deep vein 
thrombosis (DVT). It occurs in about 100 persons 
per 100,000 population each year in the United 
States and leads to about 600,000 pulmonary thrombo-
embolism (PTE) cases and also causes 60,000 deaths an-
nually (1, 2). For many years, unfractionated heparin 
(UFH) and warfarin have been used for treatment of DVT 
and prevention of PTE (3). This approach needs hospi-
talization and necessitates close monitoring by partial 
thromboplastin time (PTT) measurement (4). By devel-
opment of low molecular weight heparin (LMWH) the 
need for laboratory monitoring was resolved. In addi-
tion, some investigators also claimed that it is accompa-
nied with less bleeding risk and better outcome (5). Ac-
cordingly, outpatient management of DVT became possi-
ble and nowadays American College of Chest Physicians 
(ACCP) advocates outpatient therapy for DVT. This 
method has been shown to be safe and effective in pres-
ence of home adequacy criteria (6). Home adequacy is 
defined by ACCP as “well-maintained living conditions, 
strong support from family or friends, phone access, and 
ability to quickly return to the hospital if there is deteri-
oration” (7). Yet, many physicians in Iran prefer to hos-
pitalize all DVT patients because of their belief in the im-
possibility of outpatient treatment. 
In the current study, we evaluated outpatient therapy of 
10 patients with lower extremity DVT in emergency de-
partment (ED) of Imam Khomeini Hospital of Urmia, Iran 
from 21 July 2014 to 15th march 2015. DVT was con-
firmed by ultrasound in all 10 patients. None of them had 
previous history of DVT, PTE, use of anticoagulant, al-
lergy to heparin or warfarin, hemodynamic instability, 
home inadequacy, and comorbidity that mandate hospi-
talization. Patients received first dose of subcutaneous 
LMWH (Enoxaparin) and oral warfarin, and were dis-
charged from ED on the same day. The home medical 
prescription included subcutaneous LMWH 1mg/Kg 
twice daily, plus 5 mg oral warfarin daily. The dose of 
warfarin was adjusted based on international normal-
ized ratio (INR). The goal INR was considered 2-2.5. 
Bleeding, PTE, recurrent DVT and mortality had not hap-
pened in 2, 4, 6, and 30 days follow-up after ED dis-
charge. It seems that it is time to change our viewpoint 
in this regard. The importance of this matter is dupli-
cated when we are confronted with overcrowding of 
emergency departments and loss of hospital beds fol-
lowing implementation of Health Sector Evolution Plan 
in Iran.  
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